ZURICH, Aug 26 (Reuters) – Straumann, the world’s
largest maker of dental implants, has no interest in joining the
suitors for No.2 player Nobel Biocare, preferring
instead to go after deals in the fast-growing Chinese market, it
said on Tuesday.
The Swiss firm, battling sliding sales in its main market of
Europe, has stepped up its investments in the Asia/Pacific
region, where one in every five dental implants is sold.
LONDON/ZURICH, Aug 24 (Reuters) – Roche Holding AG
has agreed to buy U.S. biotech company InterMune Inc
for $8.3 billion in cash, marking the latest multibillion-dollar
deal in a consolidating pharmaceutical sector.
The Swiss drugmaker said on Sunday it would pay $74.00 a
share for InterMune, representing a premium of 38 percent to the
closing price on Aug. 22.
ZURICH, Aug 22 (Reuters) – Swiss drugs industry supplier
Lonza Group AG is courting the financial backers of
biotech firms to help secure a steady stream of projects and
offset some of the volatility of outsourced production
contracts, a senior executive said.
The Basel-based company has seen growing demand for its
outsourcing services over the past year as drugmakers invest in
specialised drugs that are hard to produce, such as
antibody-drug conjugates and ingredients for cell and viral
ZURICH, Aug 21 (Reuters) – Swiss engineering group ABB
has developed technology that can double the power
flow of underground cables, making it cheaper to integrate
electricity into the grid from distant offshore wind farms.
The innovation means a single high-voltage direct current
(DC) cable can now transmit up to 2.6 gigawatts (GW) of power –
enough energy to power two million homes, or serve the
electricity needs of Paris, ABB said on Thursday.
ZURICH, Aug 21 (Reuters) – Nobel Biocare, a Swiss
dental implant maker that has been approached by potential
buyers, said on Thursday that its turnaround strategy was
“unquestionably working” as it raised its forecast for
The world’s second-biggest dental implant maker declined to
comment on the progress of talks with potential buyers which it
confirmed at the end of July were at a “very early” stage.
ZURICH, Aug 20 (Reuters) – Novartis has signed a
licensing deal to hand over its experimental tuberculosis (TB)
drugs to the Global Alliance for TB Drug Development, joining a
growing Big Pharma retreat from antibiotics.
The TB Alliance deal reflects renewed scrutiny of the
Novartis portfolio under new chairman Joerg Reinhardt, who is
focusing the Swiss company’s research on core areas such as
cancer, respiratory drugs, heart failure and dermatology.
ZURICH, Aug 7 (Reuters) – Adecco, the world’s
largest staffing company by sales, expects a modest economic
recovery to keep demand for temporary workers stable in Europe
as it reported a slight slowdown in underlying revenue growth in
the second quarter.
Employment agencies like Adecco and Dutch rival Randstad
are seen as barometers for economic health since
companies tend to hire temporary workers at the start of a
recovery when they are reluctant to commit to full-time hiring.
BASEL (Reuters) – Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.
Unlike other pharmaceutical companies that have been ravaged by patent losses, Roche has yet to face a challenge to its older biotech drugs by makers of copycat treatments and has launched a string of new, expensive cancer medicines.
ZURICH, July 23 (Reuters) – Charges linked to costly delays
to offshore wind and solar power projects pushed ABB’s
second-quarter earnings below forecasts, sending its shares down
2 percent on Wednesday.
Like many of its rivals, the Swiss company is suffering from
a lack of large orders for its power equipment and is working
its way through a backlog of less profitable contracts.
ZURICH, July 22 (Reuters) – Actelion Chief
Executive Jean-Paul Clozel said he was determined to keep the
Swiss biotech company independent, batting away speculation it
could become the next takeover target for U.S. firms seeking
lower taxes by relocating abroad.
Europe’s biggest biotech company has been rumoured as a
potential tax inversion target and its strong pipeline of drugs
to treat pulmonary arterial hypertension (PAH) could also